Join

Compare · BIOC vs HUM

BIOC vs HUM

Side-by-side comparison of Biocept Inc. (BIOC) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BIOC and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
  • HUM is the larger of the two at $42.74B, about 939.9x BIOC ($45.5M).
  • HUM has hit the wire 4 times in the past 4 weeks while BIOC has been quiet.
  • HUM has more recent analyst coverage (25 ratings vs 0 for BIOC).
MetricBIOCHUM
Company
Biocept Inc.
Humana Inc.
Price
$0.41-20.43%
$355.91+1.64%
Market cap
$45.5M
$42.74B
1M return
-
+43.90%
1Y return
-
+52.72%
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NYSE
IPO
2014
News (4w)
0
4
Recent ratings
0
25
BIOC

Biocept Inc.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

HUM

Humana Inc.

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.

Latest BIOC

Latest HUM